Integra Lifesciences Holdings (IART)
NASDAQHealth CareMedical - DevicesSnapshot 2026-10-29
NASDAQHealth CareMedical - DevicesSnapshot 2026-10-29
Research Workspace
Put IART beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Revenue growth of at least 3.5% in FY26: Comparison needs review.
View ThesisRevenue growth is slowing — up about 1% over the past year and decelerating.
View GrowthManagement screens strong on capital allocation, earnings delivery.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 42% in its worst 12-month stretch.
View RiskIART’s bet rests on returning revenue growth despite Cincinnati’s lasting disruption. Revenue growth slowed from 0.8% to 2.3%, while Q3 earnings beat expectations. Q3 revenue was $411 million, and Integra cut its 2026 revenue outlook. IART trades at 5.1× P/E versus peers’ 30.3× median. The price reflects less growth than our forecast. The specific risk is the Cincinnati disruption, expected to affect revenue through Q4. Our model puts next-quarter earnings miss probability near 28%. The thesis is on watch because its growth comparison needs review. Peer multiples imply a price about 44% above where it trades. This read is provisional.
Trailing returns as of 2026-10-30. IART is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 12 analysts currently covering IART (as of Oct 2026).
Based on 4 Wall Street analysts offering 12-month price targets for IART in the last 4 months.
Continue this research
Compare IART with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| IART Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put IART next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Achieve 2026 revenue growth guidance of 0.8% to 3.3%
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $12.75
The last 12 months of price, then the range of analyst 12-month targets from today’s $12.75.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Cincinnati disruption extending into Q2 2027 threatens execution of 2026 growth guidance.

Threatens: Reduce balance sheet leverage and maintain disciplined capital allocation
Increased debt may hinder capital allocation objectives.

Threatens: Reaffirm 2026 adjusted EPS guidance of $2.40 to $2.50
Preliminary results may hinder EPS guidance reaffirmation.

Cutting 2026 outlook directly impacts revenue growth guidance.

Threatens: Reaffirm 2026 adjusted EPS guidance of $2.40 to $2.50
Cuts to 2026 guidance impact revenue and EPS outlook.

Advances: Reaffirm 2026 adjusted EPS guidance of $2.40 to $2.50
EPS beat indicates strong management performance.